In a recent interview with the Star-Ledger, New Jersey-based Celgene (NASDAQ: CELG) Chief Executive Officer Sol J. Barer, Ph.D. provided some insight as to the integration plans for Pharmion products and intellectual capital. Following is a portion of that Q&A. Q: Celgene already was expanding its presence abroad. What does adding Pharmion do for you [...]

• 392http://clsdf.com/2008/05/where-does-pharmion-go-from-here/Where+Does+Pharmion+Go+From+Here%3F2008-05-09+03%3A15%3A00admin

You know a deal is done when one goes to the Pharmion.com website and the Celgene (NASDAQ: CELG) site pulls up. Last Thursday Pharmion shareholders approved the acquisition and by Friday it was signed, sealed and delivered…$2.9B later or $25 in cash plus 0.8367 shares of Celgene for each share of Pharmion. Congratulations to both [...]

• 341http://clsdf.com/2008/03/pharmion-the-deal-is-done/Pharmion%3A+The+Deal+is+Done%212008-03-10+14%3A32%3A00admin

Just when you think the $2.9B Celgene (NASDAQ: CELG) acquisition of Pharmion (NASDAQ: PHRM) is all but a done deal enter one Steven A. Cohen of S|A|C Capital Advisors, a private asset management firm who with its sub CR Intrinsic Investments, hold in aggregate approximately 3 million shares of Pharmion and thus near 10% of [...]

• 313http://clsdf.com/2008/02/prhm-deal-not-good-enough-for-some/PRHM+Deal+Not+Good+Enough%2C+For+Some...2008-02-09+02%3A58%3A00admin

Array Biopharma (NASDAQ: ARRY) is an incredibly well positioned tour de force biopharmaceutical company with a strong balance sheet, a vast portfolio of six wholly owned compounds, and a variety of pharma partnered development efforts with AstraZeneca (NYSE: AZN), Celgene (NASDAQ: CELG), InterMune (NASDAQ: ITMN) and Roche (Swiss: RO.SW). President and CEO Robert Conway and [...]

• 310View 1 Comment...http://clsdf.com/2008/02/array-q%e2%80%99ly-report-well-positioned/Array+Q%E2%80%99ly+Report%3A+Well+Positioned%212008-02-06+04%3A44%3A00admin

A very interesting few days for Pharmion (NASDAQ: PHRM) and Celgene (NASDAQ: CELG) and how they are faring in their product approval efforts in Europe. The European Medicines Agency issued a positive opinion to recommend approval of Pharmion’s Thalidomide® for use in combination with melphalan and prednisone as first line treatment for patients with untreated [...]

• 305http://clsdf.com/2008/01/co-eu-hedge-pharmion-and-celgene/CO+EU+Hedge%3A+Pharmion+and+Celgene2008-01-30+15%3A56%3A00admin

CLSDF previously highlighted Source MDx, read the post (here)…there is nothing hotter than incorporating validated biomarkers under the umbrella of personalized medicine and that is what continues to transpire at the Source MDx Boulder headquarters. An impressive list of partners and clients of Source MDx include Abbott Labs (NYSE: ABT), Amgen (NASDAQ: AMGN), Celgene (NASDAQ: [...]

• 286http://clsdf.com/2008/01/source-mdx-and-the-band-played-on/Source+MDx%3A+And+the+Band+Played+On...2008-01-08+05%3A24%3A00admin

The $2.9B acquisition of Pharmion (NASDAQ: PHRM) by Celgene (NASDAQ: CELG) took another step towards closing the deal as the obligatory waiting period as required by the FTC and the Antitrust Improvements Act of 1976 expired, perhaps now clearing the way for smooth sailing to inking the deal in under 120 days. This is good. [...]

• 285http://clsdf.com/2008/01/pharmion-celgene-figuring-out-the-close/Pharmion+%26amp%3B+Celgene%3A+Figuring+Out+the+Close2008-01-05+18%3A24%3A00admin

OK…it was just a few weeks ago when I highlighted Celgene’s (NASDAQ: CELG) concentrated activity in Colorado bio, take a look (here). The Colorado bioscape has proved to be an incredibly active market for big pharma in the last year, accounting for nearly a whopping $7 billion in transactions! Just to quickly review these deals [...]

• 256http://clsdf.com/2007/11/celgene-snaps-up-pharmion-2-9b/Celgene+Snaps+Up+Pharmion%3A+%242.9B2007-11-19+04%3A53%3A00admin

Just what I think to be an interesting observation…that is how deep New Jersey-based Celgene (NASDAQ: CELG) has penetrated into the Colorado bio-scape. The connection appears to have initiated back in 2001 on a licensing deal with Pharmion (NASDAQ: PHRM) for Thalomid® (BTW…take a listen to Pharmion’s UBS Global Life Sciences Conference presentation from today [...]

• 224View 1 Comment...http://clsdf.com/2007/09/celgene-makes-ya-go-hmmm%e2%80%a6/Celgene+Makes+Ya+Go+Hmmm%E2%80%A62007-09-28+03%3A03%3A00admin

Array BioPharma, Inc. (NASDAQ: ARRY) and Celgene Corp. (NASDAQ: CELG) announced a worldwide strategic collaboration focused on the discovery, development and commercialization of novel therapeutics in cancer and inflammation. Celgene will make an upfront payment of $40MM to Array, in return Array will grant Celgene an option to select drugs developed under the collaboration that [...]

• 219http://clsdf.com/2007/09/array-and-celgene-form-strong-alliance/Array+and+Celgene+Form+Strong+Alliance%212007-09-25+04%3A15%3A00admin